Cancer Epidemiology最新文献

{"title":"Cholangiocarcinoma (CCA) mortality in Vietnam war era veterans.","authors":"T Bullman, W J Culpepper, Y S Cypel, F Akhtar, S W Morley, A Schneiderman, J C Weitlauf, E Garges, V J Davey","doi":"10.1016/j.canep.2024.102721","DOIUrl":"https://doi.org/10.1016/j.canep.2024.102721","url":null,"abstract":"<p><strong>Background: </strong>There is concern about the risk of cholangiocarcinoma mortality (CCA) among U.S. veterans who deployed to the Vietnam War theater. A variety of risk factors potentially related to Vietnam deployment may be associated with an increased risk of mortality from CCA. This study assessed the risk of CCA mortality among all Vietnam War era veterans, the first study to do so.</p><p><strong>Methods: </strong>The Vietnam Era Veterans Mortality Study is a retrospective mortality study of all 2.5 million veterans who served in Vietnam and Southeast Asia (theater) and the 7.3 million veterans who served elsewhere during the Vietnam War (non-theater). Mortality was followed from 1979 to 2019. Hazard ratios (HRs) calculated from Cox proportional hazards models, adjusted for sex and age, compared CCA mortality risk between theater and non-theater veterans overall and by branch of service. Branch specific crude rates of CCA were also compared between theater and non-theater veterans.</p><p><strong>Results: </strong>There were 2410 and 6502 CCA deaths among all theater and non-theater veterans respectively. Overall, there was no increased CCA mortality risk among theater versus non-theater veterans after adjusting for sex and age (hazard ratio, (HR: 1.00, 95 % CI: 0.95-1.04). When stratified by branch, the crude HRs for CCA were no different between branch-theater status groups except in non-theater Marines who had lower risk. A monotonic increase in crude rates for CCA mortality was observed in both theater and non-theater over forty years of follow-up.</p><p><strong>Conclusion: </strong>There was no increased risk of CCA mortality in theater versus non-theater U.S. Vietnam War veterans, an important and new finding. This study lacked data on environmental exposures and behavioral factors that would further inform analyses of CCA risk. Identification of Vietnam era veterans' specific risk factors for CCA would require alternate methods and data which do not exist.</p>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"102721"},"PeriodicalIF":2.4,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to lung cancer screening.","authors":"Sameer Rehman, Mike Lim, Ranjit Sidhu, Phil Ramis, Eric Rohren","doi":"10.1016/j.canep.2024.102722","DOIUrl":"https://doi.org/10.1016/j.canep.2024.102722","url":null,"abstract":"<p><strong>Introduction: </strong>Despite efforts to improve national lung cancer screening rates, only 4 % of eligible high-risk patients pursue this opportunity annually.</p><p><strong>Objective: </strong>The goal of this study was to better understand the system, provider, and patient-level barriers to lung cancer screening METHODS: 300 high-risk patients in the southern Nevada region who met the criteria for lung cancer screening were given a questionnaire during their outpatient visit for low dose chest CT from August 2023 through February 2024.</p><p><strong>Results: </strong>The most common reported barriers were absence of symptoms (38 %), not wishing to know that they had cancer (30 %), and not having awareness of the eligibility for CT screening (24 %).</p><p><strong>Conclusion: </strong>A multifactorial approach is indicated to provide education for high-risk patients to clarify the importance of early diagnosis, demonstrate accessibility and low cost for lung cancer screening, and absolve any misconceptions about lung cancer screening.</p>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"102722"},"PeriodicalIF":2.4,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding current trends and incidence projections of prostate cancer in India: A comprehensive analysis of national and regional data from the global burden of disease study (1990 -2021).","authors":"Vijay Kumar, Quazi Syed Zahiruddin, Diptismita Jena, Suhas Ballal, Sanjay Kumar, Mahakshit Bhat, Shilpa Sharma, M Ravi Kumar, Sarvesh Rustagi, Abhay M Gaidhane, Lara Jain, Sanjit Sah, Muhammed Shabil","doi":"10.1016/j.canep.2024.102719","DOIUrl":"https://doi.org/10.1016/j.canep.2024.102719","url":null,"abstract":"<p><strong>Background: </strong>The study aims to explore the burden and trends of prostate cancer (PC) in India at the state level from 1990 to 2021, using data from the Global Burden of Disease (GBD) 2021 study.</p><p><strong>Methods: </strong>The health metrics including age-standardised incidence rates (ASIR), prevalence rates (ASPR), disability-adjusted life years (ASDR), and mortality rates (ASMR) per 100,000 for PC were analysed across Indian states and union territories. Join point regression analysis was employed to identify significant changes in these metrics over time. Projection of ASIR were done using auto-regressive integrated moving average (ARIMA) model.</p><p><strong>Results: </strong>The age-wise distribution of PC showed increased in ASIR, ASPR, ASDR, ASMR among older age, majorly in the 75-79 years age group. From 1990-2021, the average annual percentage change (AAPC) in ASIR, ASPR, ASMR and ASDR increased by 157 %, 278 %, 76 % and 58 % respectively. Projections indicate a further rise in ASIR to 9.15 per 100,000 by 2031. The join point analysis showed the highest annual percentage change (APC) between 1992 and 1995 period in all health metrics. Despite Gujarat state showing the highest total percentage change in all health metrics when considering regional variations, Delhi and Kerala still remain the highest overall.</p><p><strong>Conclusion: </strong>The study emphasises the growing burden of PC in India, highlighting the need for improved diagnostic practices, localized screening guidelines, and targeted public health interventions.</p>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"102719"},"PeriodicalIF":2.4,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the quality of prostate cancer diagnosis recording in CPRD GOLD and CPRD Aurum primary care databases for observational research: A study using linked English electronic health records","authors":"Gayasha Somathilake ,&nbsp;Elizabeth Ford ,&nbsp;Jo Armes ,&nbsp;Sotiris Moschoyiannis ,&nbsp;Michelle Collins ,&nbsp;Patrick Francsics ,&nbsp;Agnieszka Lemanska","doi":"10.1016/j.canep.2024.102715","DOIUrl":"10.1016/j.canep.2024.102715","url":null,"abstract":"<div><h3>Background</h3><div>Primary care data in the UK are widely used for cancer research, but the reliability of recording key events like diagnoses remains uncertain. Although data linkage can improve reliability, its costs, time requirements, and sample size constraints may discourage its use. We evaluated accuracy, completeness, and date concordance of prostate cancer (PCa) diagnosis recording in Clinical Practice Research Datalink (CPRD) GOLD and Aurum compared to linked Cancer Registry (CR) and Hospital Episode Statistics (HES) Admitted Patient Care (APC) in England.</div></div><div><h3>Methods</h3><div>Incident PCa diagnoses (2000–2016) for males aged ≥46 at diagnosis who remained registered with their General Practitioner (GP) by age 65 and were recorded in at least one data source were analysed. Accuracy was the proportion of diagnoses recorded in GOLD or Aurum with a corresponding record in CR or HES. Completeness was the proportion of CR or HES diagnoses with a corresponding record in GOLD or Aurum.</div></div><div><h3>Results</h3><div>The final cohorts for comparisons included 29,500 records for GOLD and 26,475 for Aurum. Compared to CR, GOLD was 86 % accurate and 65 % complete, while Aurum was 87 % accurate and 77 % complete. Compared to HES, GOLD was 76 % accurate and 60 % complete, and Aurum was 79 % accurate and 70 % complete. Concordance in diagnosis dates improved over time in both GOLD and Aurum, with 93 % of diagnoses recorded within a year compared to CR, and 66 % (GOLD) and 71 % (Aurum) compared to HES. Delays of 2–3 weeks in primary care diagnosis recording were observed compared to CR, whereas most diagnoses appeared at least 3 months earlier in primary care than in HES.</div></div><div><h3>Conclusions</h3><div>Aurum demonstrated better accuracy and completeness for PCa diagnosis recording than GOLD. However, linkage to HES or CR is recommended for improved case capture. Researchers should address the limitations of each data source to ensure research validity.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102715"},"PeriodicalIF":2.4,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142743281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in recording of cancer diagnosis between datasets in England: A population-based study of linked cancer registration, hospital, and primary care data","authors":"Emma Whitfield ,&nbsp;Becky White ,&nbsp;Matthew E. Barclay ,&nbsp;Meena Rafiq ,&nbsp;Cristina Renzi ,&nbsp;Brian Rous ,&nbsp;Spiros Denaxas ,&nbsp;Georgios Lyratzopoulos","doi":"10.1016/j.canep.2024.102703","DOIUrl":"10.1016/j.canep.2024.102703","url":null,"abstract":"<div><h3>Background</h3><div>Differences in the recording of cancer case status and diagnosis date have been observed between cancer registry (CR) – the reference standard – and electronic health records (EHRs); such differences may affect estimates of cancer risk or misclassify diagnostic pathways. This study aims to quantify differences in recording of case status and date of cancer diagnosis between cancer registry and EHRs.</div></div><div><h3>Methods</h3><div>Linked primary care (Clinical Practice Research Datalink (CPRD)), secondary care (Hospital Episode Statistics (HES)) and national Cancer Registry (CR) data, were used to identify 14,301 patients with a recorded diagnosis of brain, colon, lung, ovarian, or pancreatic cancer between 1999 and 2018. Agreement in case status between datasets, differences in recorded diagnosis dates, and change in agreement over time were investigated for each cancer site.</div></div><div><h3>Results</h3><div>Between 84 % (ovary) to 92 % (colon) of diagnoses in cancer registry were also recorded in combined CPRD-HES data. Agreement with cancer registry was slightly lower in HES (78 % (ovary) to 86 % (colon)) and CPRD (61 % (ovary, pancreas) to 72 % (brain)). The proportion of CPRD-HES diagnoses confirmed in CR varied by cancer site (50 % (brain) to 86 % (lung)). Agreement between CR and HES was relatively stable within cancer sites over time. Concordance between CR and CPRD was more heterogeneous between cancer sites and over time. Best agreement in diagnosis date was observed between CR and HES (median difference 0 or 1 days, all cancer sites).</div></div><div><h3>Conclusion</h3><div>Agreement between CR and EHR data is heterogeneous across cancer sites. Concordance does not appear to have improved over time. Combined data from primary and secondary care may be sufficient to approximate case status in CR in some circumstances, but the date we consider to represent the diagnosis may impact study outcomes.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102703"},"PeriodicalIF":2.4,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142743279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in incidence, mortality and survival of gastric cancer in Xiamen, China from 2011 to 2020: A population-based study","authors":"Ahua Wu ,&nbsp;Zhinan Guo ,&nbsp;Yilan Lin,&nbsp;Jiahuang Chi,&nbsp;Yanqi Lan,&nbsp;Qun Lou,&nbsp;Haixia Zhang,&nbsp;Youlan Chen","doi":"10.1016/j.canep.2024.102718","DOIUrl":"10.1016/j.canep.2024.102718","url":null,"abstract":"<div><h3>Background</h3><div>Gastric cancer remains one of the most common cancers and the leading cause of death in China. This study aims to describe the incidence, mortality, survival rates, and their changing trends of gastric cancer in Xiamen, China from 2011 to 2020.</div></div><div><h3>Methods</h3><div>Population-based cancer registry data were used to calculate the incidence, mortality, and survival rates of gastric cancer. The study population consisted of gastric cancer patients diagnosed from January 1, 2011, to December 31, 2020, and followed up until September 30, 2023. The relative survival of gastric cancer was calculated using period methods. The change in trends was analyzed using Joinpoint regression.</div></div><div><h3>Results</h3><div>From 2011–2020, a total of 4716 new cases of gastric cancer and 3520 related deaths were reported. The crude incidence rate and age-standardized incidence rate (ASIR) were 21.82/100,000 and 16.74/100,000. The crude mortality rate and age-standardized mortality rate (ASMR) were 16.29/100,000 and 12.30/100,000. The ASIR and ASMR in males (ASIR: 24.71/100,000, ASMR: 18.75/100,000) were both more than those in females (ASIR: 9.6/100,000, ASMR: 6.55/100,000). The observed 5-year survival rate was 25.83 %, with an age standardized survival of 27.60 %. The incidence and mortality of gastric cancer showed a decreasing trend, and the 5-year ARS between 2016 and 2020 (30.03 %, 95 %CI: 28.07–32.12 %) was higher than between 2011 and 2015 ( 24.79 %, 95 %CI: 22.53–27.27 %). Furthermore, the survival rate decreased with increasing age.</div></div><div><h3>Conclusions</h3><div>From 2011–2020, the incidence and mortality of gastric cancer in Xiamen City have shown a decreasing trend, and the survival rate has significantly improved. Despite improved survival, the 5-year ARS remains low.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102718"},"PeriodicalIF":2.4,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142743280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updated cancer burden in oldest old: A population-based study using 2022 Globocan estimates.","authors":"Richa Shah, Nicolò Matteo Luca Battisti, Etienne Brain, Freddy H R Gnangnon, Ravindran Kanesvaran, Supriya Mohile, Vanita Noronha, Martine Puts, Enrique Soto-Perez-de-Celis, Sophie Pilleron","doi":"10.1016/j.canep.2024.102716","DOIUrl":"10.1016/j.canep.2024.102716","url":null,"abstract":"<p><strong>Background: </strong>The global population aged 80 years or older is expected to triple by 2050, leading to an increased cancer burden in the oldest population. This study describes the estimated cancer incidence and mortality in 2022 and projections for 2050 in the oldest old, analyzed globally and by world regions and World Bank income levels, for all sexes combined, as well as separately for males and females.</p><p><strong>Methods: </strong>Using GLOBOCAN 2022 estimates, we reported the estimated number of new cancer cases (excluding non-melanoma skin cancers), deaths, and truncated age-standardized incidence (ASIR) and mortality rates (ASMR) (per 100,000 individuals aged 80 years or older). We also presented the top five cancers by cases and deaths. Additionally, we projected the number of new cancer cases and deaths for each region in 2050, assuming no change in cancer incidence and death rates.</p><p><strong>Result: </strong>In 2022, an estimated 2.6 million new cancer cases (14 % of all cancer cases) and 2.1 million cancer deaths (22 % of all cancer deaths) occurred in the oldest old, with regional variations. Globally, lung, colorectal, and prostate cancers were the most common cancers diagnosed and leading causes of cancer death. ASIR ranged from 987 in Africa to 2044 per 100,000 in Northern America while ASMR ranged from 981 in Africa to 1769 per 100,000 in Oceania. In 2050, an estimated 7.4 million new cancer cases and 6 million cancer deaths are expected. The greatest increases are anticipated in China, India, and Africa, with increases exceeding 200 % compared to 2022 estimates.</p><p><strong>Conclusion: </strong>The growing cancer burden among the oldest old poses significant challenges to global healthcare systems, necessitating resource-tailored adaptations. These findings call for the inclusion of the oldest old in the development and implementation of cancer control policies and a better representation in cancer research.</p>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":" ","pages":"102716"},"PeriodicalIF":2.4,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Years of life lost due to cancer in Ecuador","authors":"Kevin Ricardo Espinosa-Yépez","doi":"10.1016/j.canep.2024.102717","DOIUrl":"10.1016/j.canep.2024.102717","url":null,"abstract":"<div><h3>Background</h3><div>Cancer is the leading cause of death worldwide. In the Americas, it is also one of the leading causes of death. In Ecuador, studies on the burden of disease are limited and none analyze or estimate the burden of all types of cancer in a single study. Therefore, the aim of this study is to estimate the years of life lost prematurely due to cancer in Ecuador from 2014 to 2022.</div></div><div><h3>Methods</h3><div>Cross-sectional observational analysis study. The databases of general deaths from the years 2014 to 2022, population projections from 2014 to 2021 and the population census for the year 2022 of the Republic of Ecuador were used. Deaths registered with ICD-10 code C00-C96 were included as deaths from cancer. The mortality rate and years of life lost prematurely due to cancer were estimated, considering the life tables of the Coale-Demeny West model and a standard time discount of 3 % was implemented without weighting by age.</div></div><div><h3>Results</h3><div>An increase in mortality and premature years of life lost was observed in the period 2014–2019, but in 2020 a reduction in mortality was seen in several types of cancer. In 2021 and 2022 mortality increased again, reaching the maximum peak of mortality and premature years of life lost in the entire study. Approximately 1,3 million years of life lost prematurely due to cancer were estimated. The types of cancer with the greatest number of years of life lost prematurely were malignant tumors of the stomach (188.180), uterus (117.142), which include both uterine cancer and cervical cancer, and leukemia (107.440). In men, in descending order, these were tumors of the stomach (101.112), prostate (67.624) and leukemia (55.654), while in women, these were malignant tumors of the uterus (117.142), breast (100.217) and stomach (87.067).</div></div><div><h3>Conclusions</h3><div>The results of this study provide a broader basis for debate on public health policies, efficient allocation of resources, and enable monitoring of cancer and prevention strategies over time.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102717"},"PeriodicalIF":2.4,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142704268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in incidence and survival of the four most common cancers by stage at diagnosis in Cyprus: A population-based study from 2004 to 2017","authors":"Christiana A. Demetriou ,&nbsp;Constantinos Koshiaris ,&nbsp;Olivia A. Cory ,&nbsp;Constantina Constantinou ,&nbsp;Ourania Kolokotroni ,&nbsp;Yiola Marcou ,&nbsp;Demetris Papamichael ,&nbsp;Haris Charalambous ,&nbsp;Dimitrios Vomvas ,&nbsp;Anna Demetriou ,&nbsp;Vasos Scoutellas ,&nbsp;Annalisa Quattrocchi","doi":"10.1016/j.canep.2024.102704","DOIUrl":"10.1016/j.canep.2024.102704","url":null,"abstract":"<div><h3>Background</h3><div>Breast, colorectal, lung and prostate cancers are the most frequent malignancies in Cyprus. This study estimated the incidence rate and 5-year net survival (NS) trends for these cancers, by sex, age, and tumor stage at diagnosis.</div></div><div><h3>Methods</h3><div>We analyzed data from the Cyprus Cancer Registry for adults diagnosed between 2004 and 2017, with follow-up until 2019. Tumor stage was classified into localized, regional, distant and unknown categories. We estimated the annual percentage change (APC) in incidence rates using Joinpoint regression. NS was estimated using flexible parametric models, adjusting for sex, age, stage and period of diagnosis. Multiple imputation was used to address unknown cancer stage.</div></div><div><h3>Results</h3><div>During 2004–2017, the incidence significantly increased for breast and lung cancer (APC: 1.1 % and 2.6 %, respectively), mainly among the elderly (70 +). A decreasing trend was identified for prostate cancer only among individuals aged 80 +. No temporal variations were identified for colorectal cancer incidence.</div><div>A positive time trend was identified for localized breast cancer between 2006 and 2017 (APC: 2.8 %). Conversely, a significant increase was noted at more advanced stages for lung (APC_distant: 4.1 %) and prostate (APC_regional: 7.6 %) cancers.</div><div>NS improved for all cancers, ranging between 80 % and 90 % for regional and all stages of breast cancer, localized colorectal cancer, and all stages of prostate cancer, surpassing 95 % for localized breast cancer, localized and regional prostate cancer.</div></div><div><h3>Conclusion</h3><div>The study observed increased (breast and lung) or stable (colorectal and prostate) cancer incidence and substantial improvements in 5-years NS trends for all cancer types, despite differences by sex and stage. Efforts should be intensified to reduce incidence by addressing cancer risk factors, and to improve survival by implementing and increasing the uptake of screening programs.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102704"},"PeriodicalIF":2.4,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142704269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measuring healthy life expectancy and determinants of poor perceived health: A population-based study among a subset of rare and common cancer survivors","authors":"Eline de Heus ,&nbsp;Saskia F.A. Duijts ,&nbsp;Jan Maarten van der Zwan ,&nbsp;Carla M.L. van Herpen ,&nbsp;Matthias A.W. Merkx ,&nbsp;Mark J. Rutherford ,&nbsp;Isabelle Soerjomataram","doi":"10.1016/j.canep.2024.102706","DOIUrl":"10.1016/j.canep.2024.102706","url":null,"abstract":"<div><h3>Background</h3><div>As the survival proportions for rare cancers are on average worse than for common cancers, assessing the expected remaining life years in good health becomes highly relevant. This study aimed to estimate the healthy life expectancy (HLE) of a subset of rare and common cancer survivors, and to assess the determinants of poor perceived health in rare cancer survivors.</div></div><div><h3>Methods</h3><div>To calculate HLE, survival data from the population-based Netherlands Cancer Registry of survivors of a rare cancer (i.e., ovarian cancer, thyroid cancer, Hodgkin lymphoma, non-Hodgkin lymphoma) (n=21,376) and a common cancer (i.e., colorectal cancer (CRC)) (n=76,949) were combined with quality of life (QoL) data from the PROFILES registry on a random sample of the rare (n=1025) and common cancer (n=2400) survivors. A flexible parametric relative survival model was used to estimate life expectancy (LE) and years of life lost, and multivariate logistic regression was applied to determine factors related to reported poor perceived health.</div></div><div><h3>Results</h3><div>Patients previously diagnosed with a rare cancer had an average LE of 8–36 years and were expected to spend ≥67 % of their remaining life in good health. CRC survivors had an average LE of 10 years with approximately 65 % of their remaining life expected to spend in good health. For all cancer types, those aged ≥65 years or with stage IV had the lowest HLE. Low socioeconomic status, advanced stage, and having received radiotherapy only were important predictors of poor perceived health among rare cancer survivors.</div></div><div><h3>Conclusion</h3><div>HLE can provide meaningful perspective for patients and practitioners for all cancer types, including rare cancers. Yet, data on QoL for rare cancers should be routinely collected, as such will serve as an indicator for monitoring and improving cancer care, and for enabling HLE measurements in cancer survivors.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102706"},"PeriodicalIF":2.4,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}